Table 1 Clinical characteristics and risk factors for 30-day mortality in patients with CRE BSI
All Patients (n = 94) | Survivors (n = 67) | Non-survivors (n = 27) | P value | |
|---|---|---|---|---|
Sex | 0.530 | |||
Male | 58 (61.7) | 40 (69.0) | 18 (31.0) | |
Female | 36 (38.3) | 27 (75.0) | 9 (25.0) | |
Age (years), median (IQR) | 38 (25–49) | 38 (27–49) | 33 (18–49) | 0.254 |
Charlson comorbidity score | 0.205 | |||
2 | 80 (85.1) | 59 (73.8) | 21 (26.3) | |
3–4 | 14 (14.9) | 8 (57.1) | 6 (42.9) | |
Underlying hematological disease | < 0.001 | |||
Standard-risk group | 36 (38.3) | 34 (94.4) | 2 (5.6) | |
High-risk group | 58 (61.7) | 33 (56.9) | 25 (43.1) | |
Received HSCT | 0.678 | |||
Yes | 20 (21.3) | 15 (75.0) | 5 (25.0) | |
No | 74 (78.7) | 52 (70.3) | 22 (29.7) | |
CRE isolates | 0.052 | |||
Escherichia coli | 48 (51.1) | 35 (72.9) | 13 (27.1) | |
Klebsiella pneumoniae | 36 (38.3) | 22 (61.1) | 14 (38.9) | |
Others | 10 (10.6) | 10 (100) | 0 (0) | |
MDRO carriage/infection | 0.968 | |||
Yes | 56 (59.6) | 40 (71.4) | 16 (28.6) | |
No | 38 (40.4) | 27 (71.1) | 11 (28.9) | |
Meropenem MICs (mg/L) | 0.806 | |||
> 8 | 78 (83.0) | 11 (68.8) | 5 (31.2) | |
≤ 8 | 16 (17.0) | 56 (71.8) | 22 (28.2) | |
Length of neutropenia | 0.012 | |||
≥ 14 days | 68 (76.4) | 46 (67.6) | 22 (32.4) | |
< 14 days | 21 (23.6) | 20 (95.2) | 1 (4.8) | |
Mucositis | 0.188 | |||
Yes | 29 (30.9) | 18 (62.1) | 11 (37.9) | |
No | 65 (69.1) | 49 (75.4) | 16 (24.6) | |
Pitt bacteremia score | 0.002 | |||
≥ 2 | 31 (33.3) | 16 (51.6) | 15 (48.4) | |
< 2 | 62 (66.7) | 51 (82.3) | 11 (17.7) | |
Septic shock | < 0.001 | |||
Yes | 15 (16) | 4 (26.7) | 11 (73.3) | |
No | 79 (84) | 63 (79.7) | 16 (20.3) | |
Co-infections | ||||
Pulmonary infection | 34 (36.2) | 17 (25.4) | 17 (63.0) | 0.001 |
Gastroenteritis | 15 (16.0) | 10 (14.9) | 5 (18.5) | 0.667 |
Perianal infection | 14 (14.9) | 12 (17.9) | 2 (7.4) | 0.196 |
others | 16 (17.0) | 9 (13.4) | 7 (25.9) | 0.145 |